马里婴儿呼吸道合胞病毒预防干预的成本效果:模型研究
该模型研究评估在马里婴儿中,现行单克隆抗体、长效单克隆抗体和母体疫苗预防呼吸道合胞病毒下呼吸道感染的成本效果。从社会视角、每剂3美元时,长效单克隆抗体的增量成本效果比为每避免一个伤残调整生命年1656美元(95%CI 734至9091),最可能具成本效果。母体疫苗需高于近期试验的效力才可能具成本效果。
要点
- 长效单克隆抗体在马里每剂3美元时,从政府与捐赠方视角均可能具成本效果。
- 现行单克隆抗体和母体疫苗的增量成本效果比更高,成本效果不确定性大。
- 母体疫苗需高于近期试验的效力才可能被视为具成本效果。
核心结论
- 在马里,长效单克隆抗体在每剂3美元时从政府与捐赠方视角均可能具成本效果。
- 母体疫苗需高于近期试验测得的效力才可能被视为具成本效果。
研究设计与样本
- 构建出生至6月龄婴儿按月队列的年龄别与季节别呼吸道合胞病毒下呼吸道感染风险模型。
- 参数来自马里队列研究的呼吸道合胞病毒数据及临床试验的产品效力。
- 整合参数不确定性,模拟无预防、季节性月度现行单克隆抗体、季前出生剂量长效单克隆抗体和母体疫苗接种的健康与经济结局。
- 从政府、捐赠方和社会视角计算各干预相较无预防的增量成本效果比。
主要发现
- 每剂3美元、社会视角下,现行单克隆抗体增量成本效果比为每避免一个伤残调整生命年4280美元(95%CI 1892至122434)。
- 每剂3美元、社会视角下,长效单克隆抗体增量成本效果比为每避免一个伤残调整生命年1656美元(95%CI 734至9091)。
- 每剂3美元、社会视角下,母体疫苗增量成本效果比为每避免一个伤残调整生命年8020美元(95%CI 3501至47047)。
关键数值与推荐
- 现行单克隆抗体:每剂3美元、社会视角,增量成本效果比4280美元/伤残调整生命年避免(95%CI 1892至122434)。
- 长效单克隆抗体:每剂3美元、社会视角,增量成本效果比1656美元/伤残调整生命年避免(95%CI 734至9091)。
- 母体疫苗:每剂3美元、社会视角,增量成本效果比8020美元/伤残调整生命年避免(95%CI 3501至47047)。
临床怎么用
- 为中低收入国家引入长效单克隆抗体提供成本效果证据,支持每剂3美元价格下的政策与投资决策。
- 提示母体疫苗需更高效力才可能具成本效果,决策时应结合产品效力与价格评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Low- and middle-income countries have a high burden of respiratory syncytial virus lower respiratory tract infections. A monoclonal antibody administered monthly is licensed to prevent these infections, but it is cost-prohibitive for most low- and middle-income countries. Long-acting monoclonal antibodies and maternal vaccines against respiratory syncytial virus are under development. OBJECTIVE: We estimated the likelihood of respiratory syncytial virus preventive interventions (current monoclonal antibody, long-acting monoclonal antibody, and maternal vaccine) being cost-effective in Mali. DESIGN: We modeled age-specific and season-specific risks of respiratory syncytial virus lower respiratory tract infections within monthly cohorts of infants from birth to six months. We parameterized with respiratory syncytial virus data from Malian cohort studies, as well as product efficacy from clinical trials. Integrating parameter uncertainty, we simulated health and economic outcomes for status quo without prevention, intra-seasonal monthly administration of licensed monoclonal antibody, pre-seasonal birth dose administration of a long-acting monoclonal antibody, and maternal vaccination. We then calculated the incremental cost-effectiveness ratio of each intervention compared to status quo from the perspectives of the government, donor, and society. RESULTS: At a price of $3 per dose and from the societal perspective, current monoclonal antibody, long-acting monoclonal antibody, and maternal vaccine would have incremental cost-effectiveness ratios of $4280 (95% CI $1892 to $122,434), $1656 (95% CI $734 to $9091), and $8020 (95% CI $3501 to $47,047) per disability-adjusted life-year averted, respectively. CONCLUSIONS AND RELEVANCE: In Mali, long-acting monoclonal antibody is likely to be cost-effective from both the government and donor perspectives at $3 per dose. Maternal vaccine would need higher efficacy over that measured by a recent trial in order to be considered cost-effective.
引用
- Laufer RS, Driscoll AJ, Baral R, et al. Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions. Vaccine. 2021. PMID: 34325934. doi:10.1016/j.vaccine.2021.06.086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。